Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TELADOC HEALTH, INC.

(TDOC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Teladoc Health : Baird Initiates Coverage on Teladoc With Neutral Rating, $162 Price Target

05/28/2021 | 08:11am EDT


© MT Newswires 2021
All news about TELADOC HEALTH, INC.
07/29TELADOC HEALTH : UBS Adjusts Teladoc's PT to $142 From $163, Citing Lower Chroni..
MT
07/28AFTER HOURS WATCH LIST SCORECARD : Usws, cake, tdoc,
MT
07/28TELADOC HEALTH : Oppenheimer Adjusts Teladoc PT to $220 From $250, Maintains Out..
MT
07/28TELADOC HEALTH : Deutsche Bank Downgrades Teladoc to Hold from Buy, Adjusts Pric..
MT
07/28TELADOC HEALTH : KeyBanc Adjusts Teladoc's PT to $180 from $220, Keeps Overweigh..
MT
07/28TELADOC HEALTH : Needham Adjusts Teladoc's Price Target to $205 From $235, Reite..
MT
07/28TELADOC HEALTH : SVB Leerink Adjusts Teladoc's Price Target to $218 from $266, K..
MT
07/28Top Premarket Decliners
MT
07/28TELADOC HEALTH : Barclays Adjusts Teladoc's Price Target to $170 From $240, Keep..
MT
07/27MT NEWSWIRES AFTER HOURS WATCH LIST : Usws, cake, tdoc
MT
More news
Financials (USD)
Sales 2021 2 013 M - -
Net income 2021 -504 M - -
Net Debt 2021 380 M - -
P/E ratio 2021 -44,2x
Yield 2021 -
Capitalization 23 672 M 23 672 M -
EV / Sales 2021 11,9x
EV / Sales 2022 9,16x
Nbr of Employees 4 026
Free-Float 91,3%
Chart TELADOC HEALTH, INC.
Duration : Period :
Teladoc Health, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TELADOC HEALTH, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Last Close Price 148,45 $
Average target price 203,04 $
Spread / Average Target 36,8%
EPS Revisions
Managers and Directors
Jason N. Gorevic Chief Executive Officer & Director
Mala Murthy Chief Financial Officer
David B. Snow Non-Executive Chairman
Jeff Nadler Chief Information Officer
Lewis Levy Chief Medical Officer
Sector and Competitors